A share price of Inhibikase Therapeutics Inc [IKT] is currently trading at $1.6, down -1.23%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IKT shares have gain 9.59% over the last week, with a monthly amount glided 4.58%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Inhibikase Therapeutics Inc [NASDAQ: IKT] stock has seen the most recent analyst activity on December 11, 2025, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $4. Previously, H.C. Wainwright downgraded its rating to Neutral on February 12, 2025.
Inhibikase Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.33 and $4.20. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Inhibikase Therapeutics Inc [NASDAQ: IKT] shares were valued at $1.6 at the most recent close of the market. An investor can expect a potential return of 150.0% based on the average IKT price forecast.
Analyzing the IKT fundamentals
Gross Profit Margin for this corporation currently stands at -0.9% with Operating Profit Margin at -1945.93%, Pretax Profit Margin comes in at -1813.85%, and Net Profit Margin reading is -1813.85%. To continue investigating profitability, this company’s Return on Assets is posted at -0.6, Equity is -0.57 and Total Capital is -0.7.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5200 points at the first support level, and at 1.4401 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6749, and for the 2nd resistance point, it is at 1.7499.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Inhibikase Therapeutics Inc [NASDAQ:IKT] is 11.67. As well, the Quick Ratio is 11.67, while the Cash Ratio is 5.72.
Transactions by insiders
Recent insider trading involved Sands Capital Life Sciences Pu, 10% Owner, that happened on Nov 21 ’25 when 2.07 million shares were purchased.
